Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nonprescription Nasonex Gains UK Regulator’s Support

Executive Summary

The UK MHRA is accepting comments on its recommendation to allow pharmacy sales of nonprescription Nasonex Allergy Control (mometasone furoate/100 mcg).


Related Content

Bayer Consumer Health Journey Still Short Of Destination
Deals Shaping the Medical Industry, October 2016
Bayer's ClariSpray Brings Hint Of Familiar Brand To Nasal Allergy Space
Industry Roundup: Children's Rhinocort, MusclePharm Restructuring
Bayer, Glaxo Find Steps Difficult Toward Better Margins In Consumer Product Space
Nasacort AQ Switch Gets NDAC Nod Despite Pediatric Use Concerns


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts